A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
British Journal of Dermatology2019Vol. 182(6), pp. 1348–1358
Citations Over TimeTop 10% of 2019 papers
Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, Abel Jarell, Kristian Reich, Catherine Maari, Kenneth B. Gordon, Laura K. Ferris, Richard G. Langley, Yayoi Tada, Renata Gontijo Lima, Hany Elmaraghy, Gaia Gallo, L. Renda, S‐M. Park, Russel Burge, Jerry Bagel, the IXORA‐R Study Group, Ronald Vender, Mark Lomaga, Isabelle Delorme, Chih-ho Hong, Richard G. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, C. A. L. Moon, Lani Clark, S. Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy Smith, Mark Lee, Stephen K. Tyring, Patricia Lee, Sunil Dhawan, Craig L. Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul S. Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven A. Davis, Navid Nami, Zoé Kececioglu Draelos, Lloyd Godwin, Cindy E. Owen, Megan N. Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco A. Kerdel, Seth Forman, Jeffrey S. Weinberg, José González-Chávez, Brent Boyce, Linda Stein‐Gold, Charles P. Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Maximos McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth B. Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John P. Scott, Douglas Young, Jessica Kaffenberger, Kelley Yokum, Matthew Zook, Andrew Blauvelt, Artis Truett, George Schmieder, Gary McCracken, Patrick McElgunn, James Herrmann, J.M. Suchniak, James Z. Appel, Elizabeth Barranco, Mark Lee, Jerry Bagel, Lawrence Osman, Ashley Cauthen, Neil S. Sadick, Eneida De La Torre, Kelly Taylor, David J. Cohen, Holly Hake Harris, Jennifer Soung, Vassilios Dimitropoulos, Stephen E. Miller, Cathy Barnes, Rawan Jumean‐Haddad, Suzanne Bruce, Lawrence Cheung, Scott Guenthner, Anthony A. Gaspari, Vivian Laquer, James Krell, Shahram Jacobs, Walter K. Nahm, Neil J. Korman, Boni E. Elewski, Laura K. Ferris, Kristina Callis Duffin, David M. Pariser, B. Johnson, Paul Wallace, Jeffrey B. Travers, Richard G. Fried
Abstract
Ixekizumab was noninferior to guselkumab in complete skin clearance and superior in clearing nails at week 24. Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, the safety findings were consistent with the known safety profile for ixekizumab.
Related Papers
- → Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis(2017)7 cited
- Ixekizumab approved for pediatric plaque psoriasis(2020)
- Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis(2017)
- FDA approves ixekizumab for plaque psoriasis(2016)
- Emerging targeted therapies for plaque psoriasis – impact of ixekizumab(2017)